EPHX2 and Parkinson disease: Treatment with the 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (TPPU), a potent sEH inhibitor, prevented the apoptosis in Parkin iPSC-derived dopaminergic neurons, suggesting that sEH represents a valuable target for the treatment of neurodegenerative disorders and PD (Figure 1; Ren et al., 2018).